id	等位基因	注释文本
876	TT	Patients with the rs12979860 TT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.
875	CT	Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.
874	CC	Patients with the rs12979860 CC genotype and hepatitis C infection may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.

id	证据的ID	总结
3705	1448617734	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.
3704	1447682452	Allele C is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele T.
3703	1447676829	Genotype CC is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C as compared to genotypes CT + TT.
3702	1444704894	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes CT + TT.
3701	1444665865	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.
3700	1183888954	Genotype CC is not associated with sustained virological response (svr) when treated with peginterferon alfa-2a, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes CT + TT.
3699	1183888950	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.
3698	981483885	Genotype CC is associated with increased response to peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.
3697	1448568054	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.
3696	PA166104867	Annotation of FDA Label for telaprevir and IFNL3
3695	PA166110235	Annotation of CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-2b,ribavirin and IFNL3

id	类型	评论
1299	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1298	Update	added guideline and label as evidence, updated text
1297	Update	Added PMIDs 27711230 and 28469811 to evidence, updated phenotype descriptions
1296	Note	Following curator meeting on 7/1/2020, it was agreed that variant annotations covering therapies using one or both of peginterferon 2a and 2b in addition to ribavirin and telaprevir could be combined into one clinical annotation.
1295	Update

最新招商产品更多>>